The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...
Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback